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Microalbuminuria independently predicts increased
cardiovascular risk in hypertensive patients, especially in
those with concomitant diabetes or established
cardiovascular disease. Drugs that target the
renin–angiotensin–aldosterone system reduce
microalbuminuria regardless of diabetic status. The
Irbesartan in the Management of PROteinuric patients at
high risk for Vascular Events was a multicenter, randomized,
double-blind, placebo-controlled paralleled group study in
which hypertensive patients with microalbuminuria and
increased cardiovascular risk were randomized to 20 weeks
treatment with ramipril plus irbesartan or to ramipril plus
placebo. Patients discontinued or tapered previous
antihypertensive therapy during a 14-day placebo lead-in
period. Change in albumin excretion rate from baseline to
week 20 was the primary end point. Adjusted week 20
baseline geometric ratios for ramipril plus irbesartan and
ramipril plus placebo were not significantly different.
Although differences in blood pressure reductions were
observed between the two treatments, these changes did not
affect microalbuminuria. More patients on dual therapy
achieved target blood pressure goals at week 20 than with
monotherapy. The incidence of adverse effects and
treatment-related adverse effects was similar in both groups.
Our results suggest that patients with cardiovascular risk and
relatively low albumin excretion rates in early-stage disease
may only require monotherapy with
renin–angiotensin–aldosterone blocking agents.
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Albuminuria is common in hypertensive and diabetic
patients and, independent of diabetes or renal function
impairment, is also an indicator of decreased kidney
function, increased cardiovascular (CV) risk, and a predictor
of both morbidity and mortality.1–5 In individuals with high
CV risk, the presence of even small quantities of albumin in
urine, or microalbuminuria (MAU), is an independent
predictor of poor CV prognosis.6,7 Since the association
between MAU, albuminuria, and CV risk is continuous, early
and effective intervention to halt the loss of kidney
function—thereby improving long-term CV prognosis—is
imperative. Post hoc analyses of data from the HOPE, LIFE,
RENAAL, IDNT, and AASK studies have demonstrated quite
clearly that a reduction in albuminuria correlated, in a wide
range of different hypertensive patients, with a decrease in the
risk of end-stage renal disease, CV events, and death.8–12
Baseline proteinuria is also an indicator of long-term
prognosis.
Although blood pressure reduction remains the gold
standard for CV and renal protection,13 blood pressure
control even within strict targets does not completely
eliminate albuminuria and MAU in hypertensive patients.
This has led to an increased focus on therapeutic strategies
designed toward optimal reduction of MAU in addition to
tight blood pressure control.
Agents such as angiotensin-converting enzyme (ACE)
inhibitors and angiotensin receptor blockers, that block the
renin–angiotensin–aldosterone system (RAAS), have been
shown to reduce MAU more effectively in high-risk patients
than non-RAAS-targeted therapies14,15 and are currently
recommended as part of an antihypertensive regimen in
diabetic and non-diabetic patients with renal impair-
ment.13,16 Their renoprotective and cardioprotective effects
are believed to act at least in part independently of systemic
blood pressure control.17–19
Furthermore, evidence from the converting enzyme
inhibitor in non-diabetic renal disease (COOPERATE) trial
has suggested that, in combination, an ACE inhibitor and
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2007 International Society of Nephrology
Received 16 December 2006; revised 23 May 2007; accepted 29 May
2007; published online 1 August 2007
Correspondence: GL Bakris, Department of Medicine, Hypertension Center,
University of Chicago-Pritzker School of Medicine, 5841 South Maryland
Avenue, MC 1027, Chicago, Illinois 60637, USA. E-mail: gbakris@earthlink.net
Kidney International (2007) 72, 879–885 879
angiotensin receptor blocker can achieve significant addi-
tional reductions in advanced macroalbuminuric kidney
disease to that achieved with either agent alone, at least in
patients with high levels of proteinuria.20,21 A total of 11% of
patients on combination therapy (n¼ 85) reached the
combined primary end point (time to doubling of serum
creatinine concentration or end-stage renal disease) com-
pared with 23% on trandolapril alone (hazard ratio (HR)
0.38, 95% confidence interval (CI) 0.18–0.63, P¼ 0.018;
n¼ 85) and 23% on losartan alone (HR 0.40, 95% CI
0.17–0.69, P¼ 0.016; n¼ 85).
The Irbesartan in the Management of PROteinuric
patients at high risk for Vascular Events (IMPROVE) study
was a large, randomized controlled trial designed to determine
whether combination therapy with the ACE inhibitor
ramipril and angiotensin receptor blocker irbesartan was
more effective than ramipril alone in reducing albumin
excretion rate (AER) in hypertensive patients at high CV
risk and with evidence of MAU despite prior treatment with
ACE inhibitors.
RESULTS
Patient disposition
A total of 838 patients were enrolled in the study, 405 of
whom were randomized; 204 to ramipril plus irbesartan and
201 to ramipril plus placebo (see Figure 1 for CONSORT
diagram). Most patients who were enrolled but not
randomized did not meet AER criteria after placebo lead-
in. Of the 405 patients randomized to double-blind therapy,
369 (91.1%) completed the study. In total, 20 (9.8%) and 16
(8.0%) patients in the ramipril plus irbesartan and ramipril
plus placebo groups, respectively, discontinued study med-
ication. Adverse events were the main reason for disconti-
nuation, accounting for 7 (3.4%) and 10 (5.0%) premature
withdrawals in the ramipril plus irbesartan and ramipril plus
placebo groups, respectively. Equivalent numbers of patients
in both treatment arms received the highest titrated dose of
study medication.
Baseline characteristics
Treatment groups were similar at baseline with respect to
demographics and medical history (Table 1). Patients (mean
age of 65.7 years) were predominantly male (62.0%), white
(93.1%), and diabetic (89.1%). All patients reported a CV
history and risk factors, and all but one patient had a history
of hypertension. Baseline mean seated blood pressures were
163/90 mm Hg and 164/89 mm Hg in the ramipril plus
irbesartan and ramipril plus placebo groups, respectively.
With one exception, all randomized patients reported prior
ACE inhibitor use (99.8%); treatment with enalapril (126/
405, 31.1%) and ramipril (104/405, 25.7%) was most
common. In the majority of patients (71.1%), diabetes was
the primary cause of MAU. Table 2 shows baseline geometric
means for AER for patients in the two treatment groups.
Assessed for eligibility (n=838)
Randomized (n=405)
Excluded (n=433)
Not meeting inclusion criteria (n=341)
Refused to participate (n=21)
Other reasons (n=71)
Allocated to ramipril + irbesartan (n=204)
Received intervention (n=184)
Did not receive intervention (n=0)
Allocated to ramipril + placebo (n=201)
Received intervention (n=185)
Did not receive intervention (n=0)
Lost to follow-up (n=3)
Discontinued intervention (n=17)
Adverse event (n=7)
Refused to continue (n=5)
No longer meeting inclusion criteria (n=2)
Other (n=3)
Lost to follow-up (n=0)
Discontinued intervention (n=16)
Adverse event (n=10)
Refused to continue (n=3)
No longer meeting inclusion criteria (n=1)
Other (n=1)
Death (n=1)
Analyzed (n=184)
Excluded from analysis (n=0)
Analyzed (n=185)
Excluded from analysis (n=0)
Figure 1 | CONSORT diagram for the IMPROVE study.
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Efficacy
AER baseline geometric means for subjects included in the
primary efficacy analysis were 99.6 and 103.4mg/min in the
ramipril plus irbesartan and ramipril plus placebo groups,
respectively (Figure 2). Adjusted baseline to week 20
geometric mean ratios were 0.539 for the ramipril plus
irbesartan group, a 46% decrease, and 0.584 for the ramipril
plus placebo group, a 42% decrease (Figure 2). The treatment
difference (ratio of the adjusted mean ratios) was 0.922
(P¼ 0.540) with a 95% CI of 0.711–1.195. Thus, the
combination of ramipril plus irbesartan was no more
effective in reducing AER than ramipril plus placebo. Results
showed that the ramipril plus irbesartan adjusted geometric
mean ratio was 7.8% less than the adjusted mean ratio for
ramipril plus placebo. However, the 95% CI for the point
estimate was wide indicating that the actual ramipril plus
irbesartan adjusted geometric mean ratio was anywhere from
28.9% less to 19.5% greater than that for ramipril plus
placebo. Furthermore, the actual s.d. for the primary AER
analysis was 1.27 and much higher than the s.d. of 0.73 used
in the planning of the study.22
Results for the two secondary, supportive analyses were
consistent with the primary efficacy analysis. No earlier post-
randomization data were collected for the first of these
analyses and in the second, the inclusion of subjects with an
AER of o20 mg/min had no significant effect on the results.
The study population contained only three patients with an
AER of o20 mg/min.
Subgroup analyses based on baseline AER classification
showed that for patients with MAU there was no clinically
significant difference between treatments (Figure 3). In
contrast, for subjects with overt nephropathy (baseline AER
X200 mg/min), the geometric mean AER ratio, comparing
week 20 to baseline between treatment groups, was larger,
suggesting the possibility that dual RAAS blockade provides
greater reduction of albuminuria in patients with overt
nephropathy. However, as this group included only 108
patients and the 95% CIs were large in both treatment
groups, these results must be interpreted with caution.
Change in AER from baseline to week 20 in patients with
type II diabetes showed that AER was also reduced in this
subgroup (Figure 3).
Table 1 | Patient demographics and medical history at
baseline (randomized patients)
Treatment group
Ramipril plus
irbesartan (n=204)
Ramipril plus placebo
(n=210)
Male/female (%) 123/81 (60.3/39.7) 128/73 (63.7/36.3)
Mean age (range) years 65.6 (54–91) 65.8 (54–82)
Race no. (%)
White 186 (91.2) 191 (95.0)
Black/African American 3 (1.5) 3 (1.5)
Asian 6 (2.9) 1 (0.5)
Other 9 (4.4) 6 (3.0)
Mean weight (range) kg 86.9 (54–145) 87.6 (55–148)
Medical history
Hypertension (%) 204 (100) 200 (99.5)
Type II diabetes (%) 176 (86.3) 176 (87.6)
Mean duration7s.e.
(years)
11.377.8 10.178.0
Type I diabetes (%) 7 (3.4) 2 (1)
Mean duration7s.e.
(years)
23.1714.7 7.174.4
Hypercholesterolemia (%) 132 (64.7) 132 (65.7)
Stable angina pectoris
(%)
68 (33.3) 70 (34.8)
Myocardial infarction (%) 41 (20.1) 41 (20.4)
Peripheral vascular
disease (%)
23 (11.3) 28 (13.9)
Current smoker (%) 27 (13.2) 20 (10.0)
Unstable angina pectoris
(%)
17 (8.3) 21 (10.4)
Stroke (%) 17 (8.3) 19 (9.5)
TIA (%) 8 (3.9) 11 (5.5)
Primary cause of
albuminuria
Diabetes (%) 156 (76.5) 132 (65.7)
Hypertension (%) 44 (21.6) 68 (33.8)
Non-diabetic/non-
hypertensive renal
disease (%)
2 (1.0) 0 (0)
Unknown (%) 2 (1.0) 1 (0.5)
Mean duration
albuminuria (range)
monthsa
33.91 (0.16 to 177.8) 27.32 (3.61 to 327.9)
TIA, transient ischemic attack.
aDuration of albuminuria was calculated as: (date of informed consent–date of
diagnosis +1)/30.4375. Two subjects had negative values because they were
diagnosed with albuminuria after screening.
Table 2 | AER at baseline in the ramipril plus irbesartan and
ramipril plus placebo groups (geometric mean7s.e. lg/min)
Treatment group
Ramipril plus
irbesartan (n=204)
Ramipril plus
placebo (n=201)
All patients (n=204/201) 101.977.40 106.1277.45
Microalbuminuric (o200mg/min)
patients only (n=145/137)
58.9173.12 61.2873.39
Overt nephropathy (X200mg/min)
patients only (n=59/64)
391.77720.43 343.80718.42
AER, albumin excretion rate.
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Figure 2 | Adjusted geometric mean AER from baseline to week
20 (excluding patients with AER below 20 lg/min (randomized
patients)). *Indicates adjusted geometric mean ratio (7s.e.).
Treatment difference (ratio of adjusted geometric mean
ratios)¼ 0.922 (95% CI 0.711–1.195; P¼ 0.54).
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Both treatment groups experienced reductions in blood
pressure over the 20-week double-blind treatment period
(Figure 4). Although relatively small, the reduction in both
diastolic (DBP) (P¼ 0.019) and systolic blood pressure (SBP)
(0.047) was significantly greater in patients receiving ramipril
plus irbesartan compared with those receiving ramipril plus
placebo. At week 20, more patients in the ramipril plus
irbesartan group achieved study target blood pressure of
o130/80 and o140/90 mm Hg compared with those on
ramipril and placebo (17.3 vs 10.8% and 51.9 vs 35.5%,
respectively). No significant difference was observed in
trough seated diastolic blood pressure (SeDBP) or seated
systolic blood pressure (SeSBP) between the treatment
groups in relation to baseline AER or with respect to type
II diabetes (data not shown).
Use of concomitant antihypertensive therapy increased
similarly in both groups from the end of the placebo lead-in
to the end of the study. At the end of the placebo lead-in, 98
(48%) patients in the ramipril plus irbesartan group were
using antihypertensive medication compared with 113
(56.2%) patients in the ramipril plus placebo group. This
increased to 121 (59.3%) and 136 (67.7%) patients,
respectively, by the end of the study. b-Blockers and calcium
channel blockers were the most commonly used antihyper-
tensives other than study medication.
Safety and tolerability
The addition of irbesartan to ramipril therapy was well
tolerated by patients in this study. Only seven (3.4%) patients
in the ramipril plus irbesartan group discontinued therapy
because of adverse events compared with ten (5.0%) in the
ramipril plus placebo group. The overall incidence of adverse
events and of treatment-related adverse events was similar in
the two treatment arms (Table 3). Hyperkalemia was among
the most frequently reported treatment-related adverse
events, affecting 2.5% of patients in both treatment groups.
Serious adverse events were infrequent and in the majority of
cases judged unrelated to study medication. Two patients in
the ramipril plus irbesartan group experienced serious
adverse events that may have been related to study drugs;
one patient experienced moderate acute renal failure, and the
second moderate urticaria. One patient in the ramipril plus
placebo group died from circulatory collapse during the
study, but this was not attributed to study medication.
High serum glucose, potassium, and creatinine were the
most frequently reported clinical laboratory abnormalities
(Table 3). However, mean changes from baseline to week 20
in creatinine and potassium were similar and minimal in the
two treatment groups; 0.04 mg/dl and 0.03 mEq/l in the
ramipril plus irbesartan group and 0.02 mg/dl and 0.0 mEq/l
in the ramipril plus placebo group, respectively.
Microalbuminuria
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Figure 3 | Percentage change in AER from baseline to end point
(week 20) in the ramipril plus irbesartan and ramipril plus
placebo groups by patient subgroup.
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Figure 4 | Mean change in blood pressure from baseline at 20
weeks. Adjusted mean change from baseline to week 20 in trough
(a) SeDBP and (b) SeSBP. Mean baseline blood pressures
measurements were 162.9/89.9 and 163.3/89.3 for the ramipril plus
irbesartan and ramipril plus placebo groups, respectively.
Table 3 | Frequency of treatment-emergent adverse events
and marked laboratory abnormalities (X2%)
Treatment group
Ramipril plus irbesartan
(n=204)
Ramipril plus placebo
(n=210)
Treatment-emergent adverse events, n (%)
Total 87 (42.6) 85 (42.3)
Dizziness 8 (3.9) 2 (1.0)
Headache 6 (2.9) 12 (6.0)
Hyperkalemia 6 (2.9) 6 (3.0)
Influenza 6 (2.9) 5 (2.5)
Back pain 5 (2.5) 2 (1.0)
Upper RTI 5 (2.5) 4 (2.0)
Nasopharyngitis 5 (2.5) 2 (1.0)
Cough 4 (2.0) 3 (1.5)
Diarrhea 4 (2.0) 6 (3.0)
Dyspnea 4 (2.0) 0 (0.0)
Nausea 4 (2.0) 1 (0.5)
Hypertension 3 (1.5) 7 (3.5)
Peripheral edema 3 (1.5) 4 (2.0)
Acute MI 0 (0) 4 (2.0)
Clinical chemistry,
n (%)
High serum
glucose
8/187 (4.3) 1/180 (0.6)
High potassium 3/195 (1.5) 5/194 (2.6)
High creatinine 5/194 (2.6) 6/194 (3.1)
MI, myocardial infarction.
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DISCUSSION
IMPROVE was a multicenter, randomized, double-blind,
parallel arm study designed to compare the antiproteinuric
effects of once-daily treatment of dual RAAS blockade with
irbesartan and ramipril in patients at elevated CV risk relative
to those who were receiving treatment with ramipril alone.
Secondary objectives were to compare the change from
baseline in SeDBP and SeDBP within and between treatment
groups, and to characterize the safety profile of the two
treatment strategies.
As the results of the study showed, dual RAAS blockade
with ramipril and irbesartan did not reduce MAU to a
greater extent than treatment with ramipril alone. There
was marked variability in AER values between patients,
with the 95% CI for the primary efficacy analysis much
wider than anticipated. As such, the result obtained does not
‘prove’ a lack of benefit. Numerically, the largest absolute
difference between study arms with respect to albuminuria
reduction occurred in the subgroup of patients with overt
nephropathy (macroalbuminuria). However, they repre-
sented fewer than one-third of the total study population.
With the caveat that there were only 108 patients in this
subgroup and the 95% CIs were large, this observation is
nonetheless consistent with previous studies that have
suggested that the effect of RAAS blockade may depend on
the prevailing level of albuminuria.20,21,23 In any case,
researchers designing trials to assess strategies to treat MAU
should be aware of the substantial variability in this
condition in the target population.
Results of IMPROVE suggest that patients with early-stage
disease and a relatively low AER may only require mono-
therapy with RAAS-blocking agents and that dual blockade
may provide improved reductions in AER in people with
macroalbuminuria, most of whom were likely to have
diabetic nephropathy in this study.
Significant DBP and SBP reductions were observed in
patients receiving ramipril plus irbesartan compared with
the ramipril plus placebo group. Responder rates were
also higher in patients receiving combination therapy
compared with ramipril alone. Both the JNC-7 and ESH
guidelines recommend first-line combination therapy for
patients with blood pressures of 20/10 mm Hg above goal—
patients with moderate or severe hypertension.13,16 A
majority of patients in IMPROVE required concomitant
blood pressure-lowering therapies to try and attain goal and
usage increased during the study and to a similar extent in
both treatment groups.
Dual RAAS blockade with irbesartan and ramipril was
safe and well tolerated by patients in this study, with the
incidence of adverse events and treatment-related adverse
events similar in the two treatment groups. The frequency of
adverse events typically associated with RAAS blockade, such
as hyperkalemia and increased serum creatinine, was also
similar in the two groups. In fact, the observed increases in
serum potassium and creatinine were consistent with what is
expected from treatment with ACE inhibitors.
IMPROVE was designed specifically to determine whether
the combined use of irbesartan and ramipril was more
effective than ramipril alone in reducing AER in hypertensive
patients with albuminuria and high global CV disease risk.
Providing similar blood pressure, control was achieved in
both treatment groups; it was assumed that any difference
that emerged with respect to reductions in albuminuria
would likely reflect differences in the therapeutic model of
RAAS blockade working independently of blood pressure
control.22 As our results show, the study failed to meet its
primary end point. It is important to stress that the study had
a number of limitations, not least the fact that the study
ended up being underpowered—despite careful planning—
and that it failed to recruit patients with high levels of
albuminuria. Indeed, while the majority of patients had
MAU, the study population had overall lower MAU levels
than those reported for most of the trials looking at the
effects of RAAS blockade. Conducted over a 20-week period,
the study may still have been too short to demonstrate a
positive treatment effect on MAU in the combination
treatment arm. In AASK, changes in MAU and overt
albuminuria were not evident until patients had received
treatment for at least 6–12 months.24,25 Finally, the lead-in
washout phase was short at only 14 days, which may not have
been long enough for albuminuria to return to maximum
levels before the active-treatment phase of the study. It would
have been unethical to withhold active treatment for any
longer, but this decision means that the study results may
have been affected.
It is known that AER rates can vary according to sex and
race; for example, men and Blacks found to have higher rates
in general than women or Whites.26 With over 90% of
patients being classified as White, any effect of race on the
study results is highly unlikely, although the conclusions of
the trial can therefore only be applied with confidence to this
particular ethnic group. IMPROVE enrolled men and women
in a 3:2 ratio, respectively; as men generally have higher AER
values, the unadjusted overall rates observed in this study
may have been artificially increased. However, since the
proportion of men to women was comparable between
treatment groups, this factor should not have affected the
major findings.
In conclusion, the IMPROVE study failed to demonstrate
that dual RAAS blockade with irbesartan and ramipril over
20 weeks provides better albuminuria reduction than
ramipril alone. These findings suggest that patients with
CV risk and relatively low AER in early-stage disease may
only require monotherapy with RAAS blocking agents.
However, for the treatment of hypertension, combination
achieves greater blood pressure reduction.
MATERIALS AND METHODS
The design and methodology of the IMPROVE trial has been
described in detail previously.22 In summary, eligible patients
included men and women aged X55 years with an elevated CV
risk and documented history of hypertension (4140/90 mm Hg)
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and albuminuria, as well as receiving treatment with an ACE
inhibitor (dosage equivalent to X5 mg ramipril) for a minimum of
2 months before study entry. Increased CV risk was defined as the
presence of diabetes, advanced coronary artery disease (previous
myocardial infarction, unstable angina, or angina pectoris),
peripheral vascular disease, or cerebrovascular accident. Before
randomization into the active treatment phase, a confirmed AER of
20–700 mg/min in two consecutive overnight urine collections and a
SBP X150 mm Hg and/or a DBP X95 mm Hg was required.
The major exclusion criteria were SBP o115 or X200 mm Hg
and/or DBP X115 mm Hg; febrile disease, urinary tract infection,
documented uncontrolled diabetes (HbA1c X10%), acute glomer-
ulonephritis, or other conditions affecting proteinuria; renovascular
disease or renal insufficiency; concurrent congestive heart failure;
chronic autoimmune disease; or malignancy. While pregnant or
lactating women were not eligible to participate, those of child-
bearing potential could take part providing they had a negative
pregnancy test at enrollment and were using an approved method of
contraception.
Institutional and Ethical Review Board approval for the
study protocol was granted at all participating centers, and
all patients gave written informed consent before entry into the
study. The study was conducted in accordance with the ethical
principles of the current Declaration of Helsinki Principle and
consistent with the International Conference on Harmonization
Good Clinical Practice.
Study design and treatment
This was a multicenter, randomized, double-blind, placebo-
controlled, parallel group 20-week study, in which eligible patients
were randomized to ramipril (10 mg) plus irbesartan (150–300 mg)
or ramipril (10 mg) plus placebo, following a 14-day placebo lead-in
period.22 During this time, patients discontinued or tapered
previous ACE inhibitor and other antihypertensive therapy. In this
elevated CV risk population, patients receiving b-blockers or
calcium channel antagonists for reasons other than hypertension,
for example coronary artery disease, continued stable dosing during
the placebo lead-in period. At the end of this period (week 0), all
eligible patients received open-label ramipril (5 mg once daily),
titrated to 10 mg at week 1.
At week 0, patients were also randomized in a 1:1 ratio to
irbesartan or placebo. In the irbesartan arm, following 2 weeks of
placebo to enable safe titration to target ramipril dose, irbesartan
was initiated at week 2 (150 mg once daily) for 2 weeks and then
titrated to 300 mg for the remaining 16 weeks of the study. Patients
unable to tolerate titration to maximal dose irbesartan or matching
placebo had their dosage tapered to the lower dose of irbesartan.
The control arm received ramipril plus placebo for the entire 20-
week treatment period.
During the active treatment phase, patients were set a blood
pressure goal of o130/80 mm Hg. To achieve and sustain this goal,
adjunctive antihypertensive therapy, excluding ACE inhibitors and
angiotensin receptor blockers, was permitted once patients had been
randomized to double-blind treatment and titrated to the highest
dose of study medication.
Efficacy assessments
All patients randomized to study medication were included in the
analyses of efficacy; patients with an AER below 20 mg/min, when
averaged over the two baseline qualifying measurements, were
excluded from the primary analysis (see statistical analyses). The
primary efficacy outcome measure was the change in AER from
baseline to week 20. AER was measured in two timed overnight
urine collections performed at baseline (days 12 and 13) and before
study completion at week 20. As described previously,22 all urine
samples were analyzed at a central laboratory to ensure assay
consistency. AER was calculated using the following formula: AER
(mg/min)¼ urine microalbumin (mg/l) 1/1000 (l/ml) 1000 (mg/
mg) (urine volume/collection period (ml/h)) 0.0166 (h/min).
Secondary efficacy outcome measures were the change from
baseline to week 20 in SeSBP and SeDBP. Blood pressure
measurements were performed at all study visits from screening to
days 7 and 14 of the placebo lead-in phase and weeks 0, 1, 2, 4, 6,12,
and 20 of the active treatment phase. Mean SeSBP and mean SeDBP
values were calculated from three consecutive readings.
Safety and tolerability assessments
All patients who received at least one dose of double-blind study
medication were included in the safety analysis. Safety was assessed
throughout the study with respect to the nature, frequency, and
severity of adverse events, and their relationship to study medication
as well as frequency of discontinuations due to adverse events. Other
safety measures included clinically relevant changes from baseline to
final physical examination in vital signs and changes from baseline
to end point in clinical laboratory tests.
Statistical analyses
Details of the statistical procedures used in the IMPROVE trial
have been described previously.22 In summary, change from
baseline in AER at week 20 was analyzed (with baseline and
on-therapy values transformed to their natural logarithms), using
an analysis of covariance—consisting of treatment as the main
effect and the baseline (log) value as covariate—to compare the
ramipril plus irbesartan and ramipril plus placebo groups. Change in
either group was expressed as a geometric mean ratio of week 20 to
baseline. With approximately 200 subjects randomized to each
treatment arm, the study had more than 80% power to detect a
20% reduction in the geometric mean ratio for irbesartan relative to
placebo, if such a difference truly existed. This sample size included
allowance for a 10% dropout rate and assumed an s.d. of 0.73 natural
logarithm units for the logarithmically transformed ratio of post- to
baseline AER and two-sided testing at an a-level of 0.05 for the
primary analysis.
Baseline differences in characteristics were not examined
statistically. If any clinically relevant differences were observed
between groups at baseline, a secondary supportive analysis of the
primary efficacy variable would have been carried out, adjusting for
the imbalance in any such characteristics.
In addition to the primary analysis of AER, two secondary,
supportive analyses were carried out. The first included randomized
patients with a baseline AER of o20 mg/min. The second was a last
observation carried forward analysis that included all randomized
subjects except those with an AER ofo20 mg/min. Thus the primary
analysis included data from all subjects who returned an AER result
within a very broad window of time around the week 20 visit, with
the exception of patients who had normal albumin excretion at
baseline (o20 mg/min) and were prospectively excluded from the
primary analysis. The two prospective supportive analyses put
potentially excluded data back into the analysis simply to gauge the
effect of that data on the results. This approach is similar to that
used in the analysis of AER data in both the CALM Ref.27 and
COOPERATE20,21 studies.
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Changes from baseline in SeSBP and SeDBP at week 20 were also
analyzed using analysis of covariance to compare the ramipril plus
irbesartan and ramipril plus placebo groups. The analysis model
consisted of treatment as the main effect and baseline value as
covariate. The covariate-adjusted difference between treatment
groups was tested at the two-sided 5% significance level.
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